收藏切换
Retrospective analysis of 208 nephrology patients in the treatment of roxadustat
收藏切换
PDF
Shan CHONG1, 2, Qiu-fen XIE1, Tian-tian MA3, Qian XIANG1, Ying ZHOU1, Yi-min CUI1, 2, 4
Chinese Journal of New Drugs | 2023, 32(22) : 2324 - 2328
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(22): 2324-2328
Retrospective analysis of 208 nephrology patients in the treatment of roxadustat
Full
Shan CHONG1, 2, Qiu-fen XIE1, Tian-tian MA3, Qian XIANG1, Ying ZHOU1, Yi-min CUI1, 2, 4
Affiliations
  • 1Department of Pharmacy, Peking University First Hospital, Beijing 100034, China
  • 2Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • 3Renal Division of Peking University First Hospital, Beijing 100034, China
  • 4Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, China
Published: 2023-11-30
Outline
收藏切换
Objective:

To analyze the characteristics of roxadustat utilization in our hospital's renal division, promote rational use of roxadustat, and provide evidence for a post-marketing study.

Methods:

A retrospective study was conducted. The clinical data of hospitalized patients treated with roxadustat from July 1st, 2021, to June 30th, 2022, in the renal division of our hospital were collected and analyzed.

Results:

A total of 208 medical records were included. Twenty-two (10.6%) acute kidney injury patients with anemia without the diagnosis of chronic kidney disease were treated with roxadustat. The average single dose of dialysis patients was significantly higher than that of non-dialysis patients (77.85 vs 67.37 mg, P=0.03). Sixty-three patients (30.3%) received statins, and 27 (13.0%) received sevelamer. There was significant difference between hemoglobin levels at baseline and discharge (84.80 vs 89.43 g·L-1, P=0.007). No adverse events occurred in any patient.

Conclusion:

The tolerability and safety were good in anemia patients in the renal division who were treated with roxadustat. However, there existed a few problems, such as off-label drug use, subtherapeutic dosage and drug-drug interactions. It is necessary to strengthen the intervention of clinical pharmacists and promote the rational use of roxadustat.

roxadustat  /  chronic kidney disease  /  anemia  /  rational drug use
Shan CHONG, Qiu-fen XIE, Tian-tian MA, Qian XIANG, Ying ZHOU, Yi-min CUI. Retrospective analysis of 208 nephrology patients in the treatment of roxadustat[J]. Chinese Journal of New Drugs, 2023 , 32 (22) : 2324 -2328 .
Year 2023 volume 32 Issue 22
PDF
22
6
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-11-30
Article Data
Affiliations
History
  • Accepted:2023-01-09
Funding
Affiliations
    1Department of Pharmacy, Peking University First Hospital, Beijing 100034, China
    2Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    3Renal Division of Peking University First Hospital, Beijing 100034, China
    4Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT